Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 May 22;8:156. doi: 10.3389/fonc.2018.00156

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018 Debiasi, Polanczyk, Ziegelmann, Barrios, Cao, Dignam, Goss, Bychkovsky, Finkelstein, Guindalini, Filho, Albuquerque, Reinert, de Azambuja and Olopade.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Networks for overall survival (OS) and disease-free survival (DFS). (A) OS. (B) DFS. The width of the lines represents the relative weight of the direct evidence for a given comparison, based on the number of patients included in trials. ARM 1, chemotherapy alone. ARM 2, chemotherapy + trastuzumab 12 months. ARM 3, chemotherapy + trastuzumab ≤ 6 months. ARM 4, chemotherapy (taxane + carboplatin) + trastuzumab 12 months. ARM 5, chemotherapy + lapatinib 12 months. ARM 6, chemotherapy + trastuzumab 3 months → lapatinib 9 months (sequential to trastuzumab). ARM 7, chemotherapy + trastuzumab 12 months + lapatinib (concomitant with trastuzumab). ARM 8, chemotherapy + trastuzumab 12 months + pertuzumab (concomitant with trastuzumab). ARM 9, chemotherapy + trastuzumab 12 months → NERATINIB 12 months (sequential to trastuzumab).